| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 59651-0582-30 | 59651-0582 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Dec 4, 2024 | In Use | |
| 83831-0142-50 | 83831-0142 | CARBOplatin | KYXATA | 500.0 mg/50mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 10, 2025 | In Use | |
| 51862-0083-51 | 51862-0083 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 10, 2016 | Sep 30, 2019 | No Longer Used |
| 00781-2695-44 | 00781-2695 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
| 72694-0879-10 | 72694-0879 | Vorasidenib | VORANIGO | 10.0 mg/1 | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Oral | Aug 7, 2024 | In Use | |
| 72730-0101-01 | 72730-0101 | infigratinib | TRUSELTIQ | 125.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 72205-0154-04 | 72205-0154 | NELARABINE | NELARABINE | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Oct 22, 2024 | In Use | |
| 62559-0922-51 | 62559-0922 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | Feb 28, 2023 | No Longer Used |
| 43598-0027-48 | 43598-0027 | Melphalan Hydrochloride | Melphalan Hydrochloride | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Apr 26, 2021 | In Use | ||
| 59651-0530-10 | 59651-0530 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
| 59651-0465-29 | 59651-0465 | SUNITINIB MALATE | SUNITINIB MALATE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Mar 14, 2024 | In Use | |
| 72819-0154-04 | 72819-0154 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Apr 25, 2022 | In Use | |
| 59651-0466-29 | 59651-0466 | SUNITINIB MALATE | SUNITINIB MALATE | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Mar 14, 2024 | In Use | |
| 66758-0040-01 | 66758-0040 | Methotrexate Sodium | Methotrexate Sodium | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Jun 17, 2010 | Mar 31, 2014 | No Longer Used |
| 00085-3004-05 | 00085-3004 | Temozolomide | Temodar | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 2, 2012 | In Use | |
| 68084-0284-01 | 68084-0284 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Sep 17, 2008 | In Use | |
| 00085-1519-05 | 00085-1519 | Temozolomide | Temodar | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 2, 2012 | In Use | |
| 59651-0464-29 | 59651-0464 | SUNITINIB MALATE | SUNITINIB MALATE | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Mar 14, 2024 | In Use | |
| 59651-0531-10 | 59651-0531 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
| 68382-0914-16 | 68382-0914 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 57894-0225-99 | 57894-0225 | Gemcitabine intravesical | INLEXZO | 225.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravesical | Sep 14, 2025 | In Use | |
| 66758-0047-01 | 66758-0047 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 31, 2010 | Mar 15, 2015 | In Use |
| 57894-0080-90 | 57894-0080 | Lazertinib | LAZCLUZE | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 20, 2024 | In Use | |
| 55150-0354-01 | 55150-0354 | IRINOTECAN HYDROCHLORIDE | IRINOTECAN HYDROCHLORIDE | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb 11, 2020 | In Use | |
| 57962-0140-12 | 57962-0140 | Ibrutinib | Imbruvica | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Nov 13, 2013 | In Use |
Found 12250 results — Export these results
Home